[Course of nephropathy in systemic lupus erythematosus . Influence of the treatment on clinical symptoms, renal function and histology].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D000962:Antimalarials / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use*; D001706:Biopsy; D002699:Chlorambucil / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007677:Kidney Function Tests; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D011507:Proteinuria / Q000188:drug therapy
D000974:Antibodies, Antinuclear; D000962:Antimalarials; D002699:Chlorambucil; D001379:Azathioprine; D011241:Prednisone; D007213:Indomethacin
Evolution de la néphropathie du lupus érythémateux disséminé. Influence du traitement sur la symptomatologie cliniue, les fonctions rénales et l'histologie.